- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03726983
The Effect of E-Health Management on Gestational Diabetes Control
Randomized Controlled Trail of e-Health Management for Women With Prior Gestational Diabetes Mellitus
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Background: Women with previous gestational diabetes mellitus are at increased risk for developing type2 diabetes mellitus or metabolic syndrome in their later life. Infants of mothers with GDM are more susceptible to stillbirth and more serious health concerns. With limited time for visits and the predicament of education, applying web-based intervention has become a convenient tool for health management.
Objectives: The approved project aimed to develop an e-heath management platform(eHMP) for women with high risk of gestational diabetes mellitus (GDM) and to evaluate the longitudinal effects between groups of eHMP intervention. The eHMP integrate GDM health care knowledge, self-awareness of health, self-monitoring of health status (i.e., recording weight and measurement data of metabolic syndrome risk factors and monitoring changes in data trends); participation in discussions or browsing forums; healthy lifestyle guidance and counseling; reminder systems, a token system of earning points in exchange for prizes.
Methods: Pregnant women aged 18-45 years with high risk of metabolic syndrome who have a singleton pregnancy, are eligible to participate in this study. Women who agree to participate in the study will be given a participant information sheet and consent form. Participants will be recruited from the Pregnancy diabetes Clinic, at Chang Gung memorial hospital and introduced to the eHMP using the mobile phone in the clinic. Participants will also be given the URL to access to the program and they can learn the modules at home by using their home PCs, mobile phones, or tablets. They were followed up for three times: 28 weeks' gestation, 36-40 weeks' gestation and 6-12 weeks postpartum. SPSS version 20.0 software was used to compile and analyze the research data, including questionnaires and blood test for metabolic index.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Taipei, Taiwan, 10507
- Chang Gung Memorail Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Pregnant women (pre-pregnancy body mass index ≧ 24) must meet at least one of the following conditions and agree to be interviewed:
- Age over 34 years old;
- Ever had giant infant delivery (weight ≧ 4.5 kg);
- Previous diagnosed with gestational diabetes ;
- Family history of diabetes.
Exclusion Criteria:
- Pre-existing diabetes (types 1 and 2);
- Unable to write and understand Chinese;
- Subject has cognitive impairment;
- Subject has intellectual disability or mental illness;
- Dependent on medical care (eg, anti-depressants, or any psychiatric medication)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: eHMP experimental group
The experimental group received health management support and counseling,including:
|
Pregnant women who agree to take part will be assigned to a group: experimental group and control group.
The experimental group will received health management support and counseling that were conducted by the researchers through the e-health management platform.
Andere namen:
|
Geen tussenkomst: Control group
only received usual care
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Change of Triglyceride Level
Tijdsspanne: Change from Baseline at 6-12 weeks after delivery
|
Blood sampling was performed in the fasting state.
Normal triglyceride was <150 mg/dl; ≥150mg/dl was abnormal
|
Change from Baseline at 6-12 weeks after delivery
|
Change of Fasting Blood Glucose (FBG) Level
Tijdsspanne: Change from Baseline at 6-12 weeks after delivery
|
Blood sampling was performed in the fasting state.
Normal FBG was < 100 mg/dl; ≥100mg/dl was abnormal
|
Change from Baseline at 6-12 weeks after delivery
|
Change of high-density lipoprotein cholesterol (HDL) level
Tijdsspanne: Change from Baseline at 6-12 weeks after delivery
|
Blood sampling was performed in the fasting state.
Normal HDL was ≥50 mg/dl; <50mg/dl was abnormal
|
Change from Baseline at 6-12 weeks after delivery
|
Change of Cholesterol level
Tijdsspanne: Change from Baseline at 6-12 weeks after delivery
|
Blood sampling was performed in the fasting state.
Normal Cholesterol was < 200 mg/dl; ≥200mg/dl was abnormal
|
Change from Baseline at 6-12 weeks after delivery
|
Change of systolic blood pressure
Tijdsspanne: Change from Baseline at 6-12 weeks after delivery
|
Normal systolic blood pressure was <130mmHg; ≥130mmHg was abnormal.
Blood pressure was measured at the right arm twice after a 10-min rest in the supine position by using a calibrated sphygmomanometer and averaged.
|
Change from Baseline at 6-12 weeks after delivery
|
Change of diastolic blood pressure
Tijdsspanne: Change from Baseline at 6-12 weeks after delivery
|
Normal diastolic blood pressure was <85mmHg; ≥85mmHg was abnormal.
Blood pressure was measured at the right arm twice after a 10-min rest in the supine position by using a calibrated sphygmomanometer and averaged.
|
Change from Baseline at 6-12 weeks after delivery
|
Change of body weight
Tijdsspanne: Change from Baseline at 6-12 weeks after delivery
|
Women's weight following as assessed using calibrated digital scales
|
Change from Baseline at 6-12 weeks after delivery
|
Newborn baby weight
Tijdsspanne: at birth
|
Newborn baby weight in normal range (>2500g - <4500g) - dichotomous outcome Yes/No assessed using calibrated digital scales.
|
at birth
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Change of Pregnancy Physical Activity Assessment
Tijdsspanne: Change from Baseline at 6-12 weeks after delivery
|
There are 12 items in this questionnaire, including two dimensions: exercise and inactivity.
Exercise dimension contained four items to assess the type of physical activity, intensity, duration, frequency during pregnancy.
At least 3 days per week, and each time at least 20-30 minutes, counted as regular exercise (dichotomous outcome Yes/No assessed).
Inactivity dimension contained 8 items, dichotomous outcome Yes/No assessed (score 0-8), higher values represent an inactivity lifestyle.
|
Change from Baseline at 6-12 weeks after delivery
|
Change of Dietary Behavioral Characteristics Scale
Tijdsspanne: Change from Baseline at 6-12 weeks after delivery
|
The instrument is 17-item Likert-type self-report instrument, used a 5-point response format to obtain data regarding the frequency of reported behaviors (never, rarely, sometimes, usually, always).
It including two dimensions and each scale range as: balanced diet (5 items, scale range 5-25) and diet control behavior (12 items, scale range 12-60).
Higher values represent a better maternal dietary patterns during pregnancy.
|
Change from Baseline at 6-12 weeks after delivery
|
Change of Health Promotion Scale
Tijdsspanne: Change from Baseline at 6-12 weeks after delivery
|
The instrument is 40-item Likert-type self-report instrument, used a 5-point response format to obtain data regarding the frequency of reported behaviors (never, rarely, sometimes, usually, always).
It including six dimensions and each scale range as: social-support (6 items, scale range 6-30), life-appreciation (8 items, scale range 8-40), health-responsibility (8 items, scale range 8-40), stress-management (9 items, scale range 9-45), nutritional behaviors (5 items, scale range 5-25) and exercise behaviors (4 items, scale range 4-20).
The total score was 40 to 200, higher values represent a better health promotion lifestyle.
|
Change from Baseline at 6-12 weeks after delivery
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Mei-Chen Su, Dr., Chang Gung Memorial Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 105-4129C
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Zwangerschapsdiabetes mellitus tijdens de zwangerschap
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.VoltooidDiabetes mellitus, type 1 | Diabetes type 1 | Diabetestype1 | Diabetes mellitus type 1 | Auto-immuun diabetes | Diabetes Mellitus, insulineafhankelijk | Jeugddiabetes | Diabetes, auto-immuunziekte | Insulineafhankelijke diabetes mellitus 1 | Diabetes Mellitus, insulineafhankelijk, 1 | Diabetes Mellitus,... en andere voorwaardenVerenigde Staten
-
Medical College of WisconsinMedical University of South CarolinaVoltooidSuikerziekte | Diabetes mellitus type 2 | Diabetes Mellitus bij volwassenen | Niet-insulineafhankelijke diabetes mellitus | Niet-insulineafhankelijke diabetes mellitus, type IIVerenigde Staten
-
Guang NingWervingDiabetes mellitus type 2 | Diabetes mellitus type 1 | Monogene diabetes | Pancreatogene diabetes | Door medicijnen veroorzaakte diabetes mellitus | Andere vormen van diabetes mellitusChina
-
SanofiVoltooidDiabetes mellitus type 1 - Diabetes mellitus type 2Hongarije, Russische Federatie, Duitsland, Polen, Japan, Verenigde Staten, Finland
-
Meir Medical CenterVoltooidDiabetes mellitus type 2 | Diabetes Mellitus, niet-insulineafhankelijk | Diabetes Mellitus, over orale hypoglycemische behandeling | Diabetes Mellitus bij volwassenenIsraël
-
Peking Union Medical College HospitalOnbekendDiabetes mellitus type 2 | Diabetes mellitus type 1 | Zwangerschapsdiabetes mellitus | Pancreatogene diabetes mellitus | Pregestationele diabetes mellitus | Diabetespatiënten in de perioperatieve periodeChina
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Actief, niet wervendDiabetes mellitus, type 2 | Diabetes mellitus, Type II | Diabetes Mellitus, aanvang op volwassen leeftijd | Diabetes Mellitus, niet-insulineafhankelijk | Diabetes Mellitus, niet-insuline-afhankelijkVerenigde Staten
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)VoltooidDiabetes mellitus, type 2 | Diabetes mellitus, Type II | Diabetes Mellitus, aanvang op volwassen leeftijd | Diabetes Mellitus, niet-insulineafhankelijk | Diabetes Mellitus, niet-insuline-afhankelijkVerenigde Staten
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)VoltooidDiabetes mellitus, type 2 | Diabetes mellitus, Type II | Diabetes Mellitus, aanvang op volwassen leeftijd | Diabetes Mellitus, niet-insulineafhankelijk | Diabetes Mellitus, niet-insuline-afhankelijkVerenigde Staten
-
Hoffmann-La RocheRoche DiagnosticsVoltooidDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Duitsland
Klinische onderzoeken op Experimental group
-
Chinese University of Hong KongActief, niet wervendIntellectuele handicap, MildHongkong
-
Karadeniz Technical UniversityVoltooidHemodialyse | Eenzaamheid | Geluk | Aanpassing | Dierondersteunde therapie | SymptoomKalkoen
-
University of BurgundyVoltooid
-
University of MichiganVoltooid
-
University of LisbonAssociacao Protectora dos Diabeticos de PortugalVoltooid
-
University of TennesseeNational Cancer Institute (NCI); Regional One HealthWervingGewichtsverlies | Overgewicht en obesitas | Gedrag, gezondheidVerenigde Staten
-
Loma Linda UniversityBaxter Healthcare CorporationVoltooidBloeding | Aangeboren hartfout | Chirurgie-geïnduceerde weefselverklevingenVerenigde Staten
-
Radboud University Medical CenterThe health Care Insurance Board (CVZ); Department of Preventive and Restorative...VoltooidTand, geïmpacteerdNederland
-
The Policy & Research GroupMathematica Policy Research, Inc.; The Office of Adolescent Health, HHSVoltooid
-
Cukurova UniversityVoltooidZwangerschap, hoog risico | Angst staat | SlaapkwaliteitKalkoen